8-K/A: RenovoRx Reports Record Q2 Revenue, Raises 2026 Guidance

RenovoRx announced record second quarter 2026 results with 61% sequential revenue growth, raised full-year revenue guidance to $3.75M-$4.25M, and achieved full enrollment in its Phase III TIGeR-PaC trial.

Summary

• RenovoRx reported record revenue of $909,000 for the second quarter of 2026, a 61% increase from the previous quarter and a 115% increase year-over-year.
• The company raised its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million.
• The Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC) has reached full enrollment, with topline data expected in the second half of 2027.
• RenovoCath was used for the first time in a patient with sarcoma, expanding its application beyond pancreatic cancer.
• The company ended the quarter with 21 active commercial cancer center customers, an increase of over 30% from the prior quarter, and has a pipeline of 42 additional centers.
• RenovoRx expects to reach cash-flow break-even in the fourth quarter of 2027, projecting a quarterly revenue run-rate of approximately $5 million.
• Cash and cash equivalents were $9.5 million as of June 30, 2026, which the company believes is sufficient to fund operations into the second half of 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive filing, primarily due to strong revenue growth, increased guidance, and significant clinical trial progress, indicating robust operational momentum.

Positives

• Record quarterly revenue of $909,000, up 61% sequentially and 115% year-over-year.
• Increased full-year 2026 revenue guidance to $3.75M $4.25M, representing 241%-286% year-over-year growth.
• Phase III TIGeR-PaC trial fully enrolled, a key milestone for potential future product approval.
• Expansion of RenovoCath's application to treat sarcoma, demonstrating versatility beyond pancreatic cancer.
• Significant growth in active commercial cancer center customers, reaching 21, with a pipeline of 42 additional centers.
• Strong repeat utilization from existing customers, indicating physician satisfaction and clinical utility.
• Gross profit margin remains strong at approximately 84%.
• Orphan Drug Designation received for oxaliplatin in pancreatic cancer.

Negatives

• Net loss for the quarter was approximately $2.9 million, consistent with the prior year's net loss.
• Selling, general, and administrative expenses increased significantly to $2.9 million from $1.5 million in the prior year's quarter, reflecting commercialization investments.
• Cash and cash equivalents decreased from $12.4 million to $9.5 million during the quarter, though management believes it's sufficient into H2 2027.

Risks

• The timing of clinical trial completion and data readout (expected H2 2027) could impact future strategic decisions.
• The success of commercial efforts and achievement of revenue forecasts are subject to market adoption and competition.
• The company's ability to efficiently utilize cash resources or raise additional funding is a potential concern.
• Regulatory authorities may disagree with data interpretation or development plans.
• The commercialization potential of product candidates is contingent on regulatory approval.
• Reliance on third-party suppliers and manufacturers for production.
• Uncertainty regarding pricing, coverage, and reimbursement of product candidates if approved.

Future Outlook

The company is raising and tightening its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million. Based on current trends, third quarter 2026 revenue is expected to surpass second quarter revenue. Management anticipates achieving cash-flow break-even in the fourth quarter of 2027, projecting a quarterly revenue run-rate of approximately $5 million.

Management Comments

• "In the second quarter of 2026, we delivered record revenue and executed on all three of the milestones we set for the business: revenue growth with another record revenue quarter, commercial momentum evidenced by several cancer center activations, and expansion of the application of our technology beyond locally advanced pancreatic cancer (LAPC)."
• "Our strong first half performance gives us confidence that our second half revenue will exceed our original full year forecast. This outlook is driven by more active commercial cancer center customers, more patients treated via procedures with RenovoCath, and repeat ordering across our existing customer base."
• "We continue to see meaningful repeat utilization across our existing customer base, and for the first time, a treating physician chose RenovoCath to deliver therapy to a patient with a solid tumor beyond pancreatic cancer, marking an important, physician-driven expansion of the clinical application of our TAMP platform."
• "Based on current trends, we expect third quarter revenue to surpass second-quarter revenue and set another record. We remain on track to meet or exceed our target of 36 active commercial cancer center customers by year end 2026."
• "In short, we believe RenovoRx is building a durable, capital-efficient commercial business."
• "Management believe that reaching a quarterly revenue run-rate of approximately $5 million would position RenovoRx at cash-flow break-even, and based on our current trajectory, our internal plan anticipates achieving break-even operations in the fourth quarter of 2027."

Industry Context

StockSavvy.ai notes that RenovoRx's performance aligns with a broader trend in oncology towards targeted therapies and localized drug delivery, aiming to improve efficacy while reducing systemic toxicity. The company's expansion into new solid tumor indications like sarcoma, driven by physician adoption, reflects the potential for platform technologies to address multiple unmet needs within the oncology market.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, raised guidance, and progress in clinical development.
• Patients: Continued access to innovative targeted therapy for difficult-to-treat cancers, with potential for expanded indications.
• Cancer Centers/Physicians: Increased adoption and utilization of RenovoCath, supported by growing evidence and commercial infrastructure.
• Suppliers/Creditors: Continued business operations and potential for increased demand for services and products.

Next Steps

• Continue commercialization efforts to activate new cancer center customers.
• Focus on increasing procedural utilization of RenovoCath across the customer base.
• Monitor and advance the Phase III TIGeR-PaC trial towards completion in H1 2027.
• Analyze topline data from the TIGeR-PaC trial expected in H2 2027.
• Support investigator-initiated trials to broaden the platform's evidence base.
• Explore further expansion of RenovoCath applications to other solid tumors.

Key Dates

Recommendation

The company demonstrates strong commercial execution and positive clinical progress, leading to raised guidance. However, the significant increase in SG&A expenses, continued net losses, and the long timeline for Phase III trial data readout (H2 2027) warrant a cautious approach. While the growth trajectory is impressive, the path to profitability and regulatory approval for IAG still carries inherent risks. A 'hold' position allows investors to monitor further commercial traction and clinical developments without fully committing to a growth-oriented 'buy' recommendation at this stage.

Keywords

RenovoCath, Oncology, Pancreatic Cancer, Targeted Therapy, Drug Delivery, Clinical Trial, Revenue Growth, Sarcoma